Viridian Therapeutics (VRDN)
(Delayed Data from NSDQ)
$13.47 USD
-1.37 (-9.23%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $13.48 +0.01 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
VRDN 13.47 -1.37(-9.23%)
Will VRDN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VRDN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VRDN
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Lags Revenue Estimates
Strength Seen in Viridian Therapeutics (VRDN): Can Its 8.7% Jump Turn into More Strength?
VRDN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates
How Much Upside is Left in Viridian Therapeutics, Inc. (VRDN)? Wall Street Analysts Think 97.81%
Other News for VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Buy Rating Affirmed for Viridian Therapeutics Amid Positive Outlook on VRDN-001 for Thyroid Eye Disease
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Viridian Therapeutics (VRDN) and Impedimed Limited (OtherIPDQF)
Viridian Therapeutics: Key Inflection Points Ahead
Viridian Therapeutics (VRDN) Gets a Buy from RBC Capital